drugset / Trial / NCT00216515

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

NCT00216515

Phase 4 Completed 102 enrolled Janssen Korea, Ltd., Korea
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients affects their activities of daily living, and the global benefit of galantamine.

Timeline

Start
2004-03
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 16 mg

Indications